Literature DB >> 2086699

Enhanced clearance from plasma of low density lipoproteins containing a truncated apolipoprotein, apoB-89.

K G Parhofer1, A Daugherty, M Kinoshita, G Schonfeld.   

Abstract

Previously we have reported on a kindred with hypobetalipoproteinemia in which three sisters were found to be compound heterozygotes for two newly described truncated forms of apoB. apoB-40 and apoB-89. ApoB-89-containing low density lipoproteins (LDL) bound with increased affinity to cultured normal human fibroblasts and were internalized and degraded at increased rates, suggesting that the low plasma concentrations of apoB-89-LDL of the patients could be due to enhanced rates of clearance through LDL-receptors. To examine this hypothesis, apoB-89-LDL was isolated from the three study subjects and apoB-100-LDL from two control subjects. LDL was conjugated to the radioiodinated residualizing label, dilactitol tyramine (*I-DLT, containing either 125I or 131I). *I-DLT-apoB-89-LDL and *I-DLT-apoB-100-LDL were simultaneously injected into ear veins of rabbits. The clearance from plasma and hepatic accumulations of both radiolabeled LDL fractions were followed over 24 h. Fractional catabolic rates (FCR) of apoB-89-LDL were 0.105 +/- 0.012 h-1 compared to 0.054 +/- 0.007 h-1 for apoB-100-LDL. In agreement with the enhanced clearance from plasma, 1.72 to 1.87 times more *I-DLT-apoB-89-LDL than *I-DLT-apoB-100-LDL accumulated in the livers 24 h after injection. There was no significant difference in splenic accumulation, suggesting that LDL-receptors rather than scavenger receptors mediated the enhanced clearance of apoB-89-LDL. To assess further the importance of LDL-receptors, *I-DLT-apoB-89-LDL and *I-DLT-apoB-100-LDL were reductively methylated to inhibit their interactions with LDL-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2086699

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB.

Authors:  R A Srivastava; L Toth; N Srivastava; M E Hinsdale; N Maeda; A B Cefalu; M Averna; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

2.  Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.

Authors:  J Boren; I Lee; W Zhu; K Arnold; S Taylor; T L Innerarity
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 3.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

4.  Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene.

Authors:  E Kim; C M Cham; M M Véniant; P Ambroziak; S G Young
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo.

Authors:  K G Parhofer; P H Barrett; D M Bier; G Schonfeld
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

Review 6.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

7.  Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis.

Authors:  Mindy C W Lam; Janakie Singham; Robert A Hegele; Maziar Riazy; Matti A Hiob; Gordon Francis; Urs P Steinbrecher
Journal:  Case Rep Gastroenterol       Date:  2012-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.